HU231500B1 - Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére - Google Patents

Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére Download PDF

Info

Publication number
HU231500B1
HU231500B1 HU1900121A HUP1900121A HU231500B1 HU 231500 B1 HU231500 B1 HU 231500B1 HU 1900121 A HU1900121 A HU 1900121A HU P1900121 A HUP1900121 A HU P1900121A HU 231500 B1 HU231500 B1 HU 231500B1
Authority
HU
Hungary
Prior art keywords
autism spectrum
spectrum disorder
cyclohexane derivatives
treating autism
carbamoyl
Prior art date
Application number
HU1900121A
Other languages
English (en)
Inventor
Roman Viktor Dr
Adham-Parangi Nika
Roger Earley Willie
Po-Jen Yeung Paul
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Priority to HU1900121A priority Critical patent/HU231500B1/hu
Priority to TW109108018A priority patent/TW202103701A/zh
Priority to ARP200101001A priority patent/AR118634A1/es
Priority to KR1020217036553A priority patent/KR20210151162A/ko
Priority to PCT/IB2020/053382 priority patent/WO2020208564A1/en
Priority to BR112021019367A priority patent/BR112021019367A2/pt
Priority to CN202080027793.XA priority patent/CN113677345A/zh
Priority to JP2021559605A priority patent/JP2022527386A/ja
Priority to EA202192717A priority patent/EA202192717A1/ru
Priority to EP20719737.7A priority patent/EP3952872B1/en
Priority to AU2020271363A priority patent/AU2020271363A1/en
Priority to GEAP202015793A priority patent/GEP20237554B/en
Priority to SG11202110421YA priority patent/SG11202110421YA/en
Priority to MX2021012321A priority patent/MX2021012321A/es
Priority to UY0001038657A priority patent/UY38657A/es
Publication of HUP1900121A1 publication Critical patent/HUP1900121A1/hu
Priority to IL287076A priority patent/IL287076A/en
Priority to CL2021002632A priority patent/CL2021002632A1/es
Priority to ZA2021/08429A priority patent/ZA202108429B/en
Publication of HU231500B1 publication Critical patent/HU231500B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU1900121A 2019-04-10 2019-04-10 Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére HU231500B1 (hu)

Priority Applications (18)

Application Number Priority Date Filing Date Title
HU1900121A HU231500B1 (hu) 2019-04-10 2019-04-10 Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
TW109108018A TW202103701A (zh) 2019-04-10 2020-03-11 用於治療泛自閉症障礙之胺甲醯基環己烷衍生物
ARP200101001A AR118634A1 (es) 2019-04-10 2020-04-08 Derivados del carbamoil-ciclohexano para tratar el trastorno del espectro autista
EP20719737.7A EP3952872B1 (en) 2019-04-10 2020-04-09 Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
SG11202110421YA SG11202110421YA (en) 2019-04-10 2020-04-09 Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
BR112021019367A BR112021019367A2 (pt) 2019-04-10 2020-04-09 Trans-n-[4-[2-[4-(2,3-diclorofenil)piperazin-1-il]etil]ciclo-hexil]-n?, n?-dimetilureia, uso de trans-n-[4-[2-[4-(2,3-diclorofenil)piperazin-1-il]etil]ciclo-hexil]-n?, n?-dimetilureia, composição farmacêutica, e, método para tratar uma doença ou transtorno
CN202080027793.XA CN113677345A (zh) 2019-04-10 2020-04-09 用于治疗孤独症谱系障碍的氨基甲酰基环己烷衍生物
JP2021559605A JP2022527386A (ja) 2019-04-10 2020-04-09 自閉症スペクトラム障害を治療するためのカルバモイルシクロヘキサン誘導体
EA202192717A EA202192717A1 (ru) 2019-04-10 2020-04-09 Производные карбамоилциклогексана для лечения расстройства аутистического спектра
KR1020217036553A KR20210151162A (ko) 2019-04-10 2020-04-09 자폐 범주성 장애를 치료하기 위한 카바모일 사이클로헥산 유도체
AU2020271363A AU2020271363A1 (en) 2019-04-10 2020-04-09 Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
GEAP202015793A GEP20237554B (en) 2019-04-10 2020-04-09 Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
PCT/IB2020/053382 WO2020208564A1 (en) 2019-04-10 2020-04-09 Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
MX2021012321A MX2021012321A (es) 2019-04-10 2020-04-09 Derivados del carbamoil-ciclohexano para tratar el trastorno del espectro autista.
UY0001038657A UY38657A (es) 2019-04-10 2020-04-13 Derivados de carbamoil-ciclohexano para tratar el trastorno del espectro del autismo
IL287076A IL287076A (en) 2019-04-10 2021-10-07 History of carbamoyl cyclohexane for the treatment of autism spectrum disorder
CL2021002632A CL2021002632A1 (es) 2019-04-10 2021-10-08 Derivados del carbamoil-ciclohexano para tratar el trastorno del espectro autista
ZA2021/08429A ZA202108429B (en) 2019-04-10 2021-10-29 Carbamoyl cyclohexane derivatives for treating autism spectrum disorder

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU1900121A HU231500B1 (hu) 2019-04-10 2019-04-10 Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére

Publications (2)

Publication Number Publication Date
HUP1900121A1 HUP1900121A1 (hu) 2020-10-28
HU231500B1 true HU231500B1 (hu) 2024-04-28

Family

ID=89992883

Family Applications (1)

Application Number Title Priority Date Filing Date
HU1900121A HU231500B1 (hu) 2019-04-10 2019-04-10 Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére

Country Status (18)

Country Link
EP (1) EP3952872B1 (hu)
JP (1) JP2022527386A (hu)
KR (1) KR20210151162A (hu)
CN (1) CN113677345A (hu)
AR (1) AR118634A1 (hu)
AU (1) AU2020271363A1 (hu)
BR (1) BR112021019367A2 (hu)
CL (1) CL2021002632A1 (hu)
EA (1) EA202192717A1 (hu)
GE (1) GEP20237554B (hu)
HU (1) HU231500B1 (hu)
IL (1) IL287076A (hu)
MX (1) MX2021012321A (hu)
SG (1) SG11202110421YA (hu)
TW (1) TW202103701A (hu)
UY (1) UY38657A (hu)
WO (1) WO2020208564A1 (hu)
ZA (1) ZA202108429B (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114588162B (zh) * 2022-03-30 2023-10-27 中国人民解放军空军军医大学 拉莫三嗪治疗孤独症触觉异常的应用
US11980603B2 (en) 2022-06-11 2024-05-14 AMS Therapeutics, LLC Method of treating expressive language deficit in autistic humans

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
CN101801381B (zh) 2007-05-11 2013-08-14 里克特格德翁公司 氨基甲酰基-环己烷衍生物的溶剂合物和结晶形式
HU230748B1 (hu) 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása
HUP0700353A2 (en) 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
WO2009020897A1 (en) 2007-08-03 2009-02-12 Forest Laboratories Holdings Limited Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
UA104869C2 (uk) 2008-07-16 2014-03-25 Ріхтер Гедеон Нірт. Фармацевтичні композиції, що містять ліганди рецептора дофаміну
WO2011060363A2 (en) 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
HUE036035T2 (hu) 2013-12-13 2018-06-28 Pf Medicament Kromon-származék mint dopamin-D3 receptor antagonista autizmus spektrum betegség kezelésében történõ alkalmazásra

Also Published As

Publication number Publication date
MX2021012321A (es) 2021-11-12
AU2020271363A1 (en) 2021-11-18
TW202103701A (zh) 2021-02-01
SG11202110421YA (en) 2021-10-28
EA202192717A1 (ru) 2022-01-17
CN113677345A (zh) 2021-11-19
UY38657A (es) 2020-10-30
JP2022527386A (ja) 2022-06-01
EP3952872B1 (en) 2024-03-13
ZA202108429B (en) 2022-09-28
AR118634A1 (es) 2021-10-20
IL287076A (en) 2021-12-01
EP3952872A1 (en) 2022-02-16
BR112021019367A2 (pt) 2021-12-07
WO2020208564A1 (en) 2020-10-15
CL2021002632A1 (es) 2022-05-06
KR20210151162A (ko) 2021-12-13
HUP1900121A1 (hu) 2020-10-28
GEP20237554B (en) 2023-10-25

Similar Documents

Publication Publication Date Title
IL285573A (en) mechanochemical process
EP3297644A4 (en) Methods for treating autism spectrum disorder and associated symptoms
EP3245809A4 (en) Architecture for simultaneous spectrum usage by air-to-ground and terrestrial networks
EP3295602A4 (en) Methods and apparatus for partial subframe transmission and broadcast channel on unlicensed spectrum
EP3400010A4 (en) ANTI-HER2 COMBINATIONS FOR THE TREATMENT OF TUMORS
EP3601563A4 (en) ANALYSIS OF AUTISM SPECTRUM DISORDER
WO2016179558A8 (en) K-ras modulators
ZA202108429B (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
IL280128A (en) A method for treating epilepsy
GB2586597B (en) Dual-comb spectroscopy
EP3774743A4 (en) PRODRUG COMPOUNDS ACTIVATED BY AKR1C3 AND USED IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
EP3595615A4 (en) TREATMENT OF GINGIVITIS
EP3579836A4 (en) PROCEDURES FOR THE PHARMACOTHERAPY OF AUTISTIC SPECTRUM DISORDERS
EP4048249A4 (en) METHOD FOR TREATING THE SYMPTOMS OF AUTISM SPECTRUM DISORDER
EP3954368A4 (en) LINK TO THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP3962919A4 (en) Compounds for treating cancer
EP3769759A4 (en) AGENTS FOR TREATMENT OF EPILEPSY
GB201909468D0 (en) Compounds for treating cancer
EP4081223A4 (en) THERAPEUTIC MOLECULES AGAINST SEPSIS
EP3948275A4 (en) DIAGNOSIS OF CHILDREN'S RISK FOR AUTISTIC SPECTRUM DISEASE
EP3854392A4 (en) USE OF A CARBAMATE COMPOUND FOR THE PREVENTION, ATTENUATION OR TREATMENT OF CONCOMITANT EPILEPTIC SEIZURES
EP4046637A4 (en) EXTERNAL PREPARATION FOR THE TREATMENT OF EPILEPSY OR AN AUTISTIC SPECTRUM DISORDER
EP3744332A4 (en) AGENT INTENDED TO RELIEVE AUTISTIC SPECTRUM DISORDER AND MENTAL ILLNESS
EP3400939A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER
PT3921026T (pt) Carotenoides c50 para o tratamento ou a prevenção da náusea